lower expect dmd drug share
action reflect latest updat develop
duchenn muscular dystrophi competit landscap rais
forecast slightli onward nippon shinyaku howev
market interest wind reduc target price
potenti return maintain
invest overview compani post posit top-line data
north american phase japanes phase studi
howev market turn attent sarepta develop
gene therapi program contribut drop nippon shinyaku
share price believ treatment option patient
amen gene therapi focu compani remain uptravi
pulmonari arteri hypertens increas contribut earn
oversea uptravi sale growth slow sinc johnson johnson
took respons greater uptak boost sale activ
necess nippon shinyaku share price recov
catalysts/risk expect see updat quarterli ex-japan sale
uptravi jnj earn result schedul juli end
year look present clinic data benefit
function activ anticip compani file approv us
japan within fiscal year risk includ uptravi sale trend
market expect delay develop myelofibrosi
valuat target price deriv ep
previous price-to-earnings base averag
month forward price-to-earnings bloomberg estim last six month
valuat metric
chang tp
number share mn
price month
price rel chart measur perform
topix close
spot exchang rate
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
price jul upsid rate outperform target price analyst yen ting chen
profit tax
issuanc retir stock
net chang cash
number share mn
chang estim
base data north american phase japanes phase studi
releas june rais probabl success assumpt
japan us hand given latest
develop competitor gene therapi dmd reduc market share
assumpt grow expect high efficaci gene therapi still
earli stage develop issu remain long-term safeti durat
efficaci stabl manufactur suppli furthermor estim
patient pre-exist neutral antibodi viru use deliv
gene limit efficaci treatment base current method current
forecast assum bear scenario gene therapi fulli approv
launch late us japan patient penetr
peak even situat rais sale estim due increas
success rate assumpt outweigh reduct market share refer
bull scenario assum gene therapi launch sale
would current forecast
figur chang assumpt sale forecast
figur sale forecast
figur impact consolid ep
impact earn
previou forecast estim would contribut ep
current forecast impact increas
hand uptravi continu key product compani estim
licensing/royalti revenu uptravi amount compani annual op
figur major op uptravi licensing/royalti revenu
licens revenu op
target price base ep previous
forward price-to-earnings multipl base averag
forward price-to-earnings bloomberg estim last six month sinc two day sarepta
present gene therapi data june japan time share price drop
price-to-earnings averag well compani averag last two
figur forward price-to-earnings trend nippon
figur share price trend nippon shinyaku
urinari disord caus bph
cancer chronic pain
dev
file
dev
royalti licens
figur profit loss statement
profit tax
compani mention price
